PELP1 and breast cancer: Importantly, silencing of PELP1 using a liposomal formulation to vehicle PELP1 siRNA in vivo was shown to be significantly effective in reducing the growth of an orthotopic model of ER positive breast cancer [37], suggesting that targeting this protein is feasible in vivo and could have promising therapeutic effects.